Sacituzumab Govitecan for Triple-Negative Breast Cancer: Aditya Bardia, MD

Recently, the FDA granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics, Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease. The FDA had previously granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the phase 3 ASCENT study (NCT02574455)...
Continue reading

Pembrolizumab FDA Approved for Triple-Negative Breast Cancer

The FDA recently approved pembrolizumab (Keytruda®, Merck & Co) with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) for those whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. In addition, the FDA approved the companion diagnostic, PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.), to select patients with TNBC for pembrolizumab. Efficacy was shown in KEYNOTE-355 (NCT02819518), a multicenter, double-bl...
Continue reading

Does Adjuvant Chemotherapy Benefit Small, Node-Negative TNBC?

Researchers set out to investigate the association between adjuvant chemotherapy and outcomes in patients with small, node-negative, triple-negative breast cancer (TNBC) and found that whereas adjuvant chemotherapy was associated with increased overall survival (OS) in older patients with pT1b tumors, younger patients with pT1a tumors experienced higher rates of mortality. For this observational study, results of which are published in JAMA Oncology, 16,180 patients from the National Cancer Data...
Continue reading

Metronomic Capecitabine Maintenance for TNBC: Zhongyu Yuan, MD

Metronomic capecitabine maintenance therapy has been shown to be more effective compared with observation for patients with triple-negative breast cancer (TNBC), according to a study led by Zhongyu Yuan, MD. Results of the study have been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this interview with i3 Health, Dr. Yuan shares insights on treating TNBC and future directions in the TNBC treatment landscape. What are the most challenging aspec...
Continue reading

TNBC: Metronomic Capecitabine Maintenance Improves Outcomes

Metronomic capecitabine maintenance after standard treatment has been shown to be a successful therapy for patients with triple-negative breast cancer (TNBC) in a recent study. Results of this study will be reported on later this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Relapse and unfavorable outcomes are still issues among patients with TNBC. According to lead study author XI Wang, MD of the Department of Breast Oncology at Sun Yat-Sen Universit...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.